Nivolumab vs Sasanlimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT01673867 · Phase 3 · completed

This was a large randomized trial comparing nivolumab with active treatment, but it was open-label rather than double-blinded. The prespecified primary endpoint, overall survival, favored nivolumab and was statistically significant; however, the lack of blinding limits the strength of the evidence.

Next expected readout: November 2026 · NCT02955290 (registry estimate)

Reported efficacy

Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68) (met)

Result source: NCT01673867

Sasanlimab

Developed by Pfizer

Phase 2/3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT04181788 · Phase 1/2 · completed

Phase 1/2 open-label study in advanced malignancies (155 participants). The primary endpoints are dose-limiting toxicities and pharmacokinetic exposure, reported descriptively; no efficacy hypothesis was tested as a primary comparison.

Reported efficacy

Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1b: at the end of cycle 1 (28 days) for the PF-06801591 300 mg SC Q4W arms, and (42 days) for the PF-06801591 600 mg SC Q6W arms); Phase 2: AUCτ of PF-06801591 at Steady State (Phase 2: Cycle 4 Day 1, 8, 15, 22 and Cycle 5 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1, 8, 15, 29 and Cycle 4 Day 1 for the PF-06801591 600 mg SC Q6W arm); Phase 2: Ctrough of PF-06801591 at Steady State, at Week 12 (Phase 2: Cycle 4 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1 for the PF-06801591 600 mg SC Q6W arm): Dose-limiting toxicities in phase 1b: 0 participants in each of the four arms (sasanlimab 300 mg SC Q4W escalation and expansion, 600 mg SC Q6W escalation and expansion); no comparator arm. (not_applicable)

Result source: NCT04181788

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointNivolumabSasanlimab
PFS, median12.1 vs 8.1+4 vs placebon 275NCT03117049
22 other results
—Trial running · NCT06218069
OS, median12.2 vs 9.4vs Docetaxeln 292NCT01673867
20 other results
14.7b300 mg SC · n 68NCT02573259
1 other result
  • 10.9 300 mg SC · n 39 · Phase 1 · secondary NCT02573259
ORR61.5% vs 50.5%+11 vs placebon 275NCT03117049
19 other results
  • 19.5% vs 12.8% n 292 · Phase 3 · secondary NCT01673867
  • 20% vs 8.8% n 135 · Phase 3 · secondary NCT01642004
  • 36.4% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 27.5% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 26.2% vs 29.7% n 187 · Phase 3 · secondary NCT02477826
  • 37.9% vs 29.7% n 177 · Phase 3 · secondary NCT02477826
  • 52.3% vs 29.7% n 377 · Phase 3 · secondary NCT02477826
  • 38.1% vs 29.7% n 126 · Phase 3 · secondary NCT02477826
  • 67.6% vs 64.5% n 287 · Phase 3 · secondary NCT04026412
  • 72.2% vs 64.5% n 320 · Phase 3 · secondary NCT04026412
  • 61.3% vs 57.9% n 287 · Phase 3 · secondary NCT04026412
  • 63.1% vs 57.9% n 320 · Phase 3 · secondary NCT04026412
  • 26.1% vs 33.5% n 211 · Phase 3 · secondary NCT02041533
  • 50.6% vs 43% wk 64 · n 158 · Phase 2 · primary NCT04623775
  • 14.5% 3 mg/kg · n 117 · Phase 2 · primary NCT01721759
  • 17.1% 480mg Q4W · n 129 · Phase 2 · secondary NCT03090737
  • 15.4% 3 mg/kg · n 117 · Phase 2 · secondary NCT01721759
  • 32.3% n 288 · Phase 2 · secondary NCT02659059
  • 47.2% n 36 · Phase 2 · secondary NCT02659059
16.4%b300 mg SC · n 67NCT02573259
3 other results
  • 18.4% 300 mg SC · n 38 · Phase 1 · primary NCT02573259
  • 19.4% 300 mg SC · n 67 · Phase 1 · primary NCT02573259
  • 21.1% 300 mg SC · n 38 · Phase 1 · primary NCT02573259
Duration of response, median11 vs 7+4 vs placebon 275NCT03117049
12 other results
—Trial running · NCT06218069

PFS, median

Nivolumab
12.1 vs 8.1+4 vs placebon 275NCT03117049
22 other results
Sasanlimab
—Trial running · NCT06218069

OS, median

Nivolumab
12.2 vs 9.4vs Docetaxeln 292NCT01673867
20 other results
Sasanlimab
14.7b300 mg SC · n 68NCT02573259
1 other result
  • 10.9 300 mg SC · n 39 · Phase 1 · secondary NCT02573259

ORR

Nivolumab
61.5% vs 50.5%+11 vs placebon 275NCT03117049
19 other results
  • 19.5% vs 12.8% n 292 · Phase 3 · secondary NCT01673867
  • 20% vs 8.8% n 135 · Phase 3 · secondary NCT01642004
  • 36.4% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 27.5% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 26.2% vs 29.7% n 187 · Phase 3 · secondary NCT02477826
  • 37.9% vs 29.7% n 177 · Phase 3 · secondary NCT02477826
  • 52.3% vs 29.7% n 377 · Phase 3 · secondary NCT02477826
  • 38.1% vs 29.7% n 126 · Phase 3 · secondary NCT02477826
  • 67.6% vs 64.5% n 287 · Phase 3 · secondary NCT04026412
  • 72.2% vs 64.5% n 320 · Phase 3 · secondary NCT04026412
  • 61.3% vs 57.9% n 287 · Phase 3 · secondary NCT04026412
  • 63.1% vs 57.9% n 320 · Phase 3 · secondary NCT04026412
  • 26.1% vs 33.5% n 211 · Phase 3 · secondary NCT02041533
  • 50.6% vs 43% wk 64 · n 158 · Phase 2 · primary NCT04623775
  • 14.5% 3 mg/kg · n 117 · Phase 2 · primary NCT01721759
  • 17.1% 480mg Q4W · n 129 · Phase 2 · secondary NCT03090737
  • 15.4% 3 mg/kg · n 117 · Phase 2 · secondary NCT01721759
  • 32.3% n 288 · Phase 2 · secondary NCT02659059
  • 47.2% n 36 · Phase 2 · secondary NCT02659059
Sasanlimab
16.4%b300 mg SC · n 67NCT02573259
3 other results
  • 18.4% 300 mg SC · n 38 · Phase 1 · primary NCT02573259
  • 19.4% 300 mg SC · n 67 · Phase 1 · primary NCT02573259
  • 21.1% 300 mg SC · n 38 · Phase 1 · primary NCT02573259

Duration of response, median

Nivolumab
11 vs 7+4 vs placebon 275NCT03117049
12 other results
Sasanlimab
—Trial running · NCT06218069
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Nivolumab: 6 of 6 rows · Sasanlimab: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricNivolumab
Rows use multiple source trials
Sasanlimab
ORR
responder rate · % of participants
No placebo or comparator arm
17.1% (n=129)480mg Q4Wa,b,c,d
NCT03090737 · Phase 2 · registry result, not featured evidence
4 other source trials
32.3% (n=288)
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
47.2% (n=36)
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
14.5% (n=117)3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
15.4% (n=117)3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
16.4% (n=67)300 mg SCe,a,b,c,d
NCT02573259 · Phase 1 · registry result, not featured evidence
show 3 more doses
19.4% (n=67)300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
18.4% (n=38)300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
21.1% (n=38)300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
Overall Survival
time to event · months
No placebo or comparator arm
NA monthse,a,b,d
NCT03158129 · Phase 2 · registry result, not featured evidence
show 3 more doses
NA months
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
14.7 months300 mg SCe,a,b,d
NCT02573259 · Phase 1 · registry result, not featured evidence
show 1 more dose
10.9 months300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
Dropout rate
—480 mgf
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 43 more results
—3 mg/kg
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
1.7%Nivolumab
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—480 mg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—3 mg/kg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
3%Nivolumab
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
1.7%360 mg
NCT02998528 · Phase 3 · combination
0.9%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · combination
1.3%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3
1.3%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · combination
1.1%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · combination
2.8%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · combination
0.5%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · combination
0%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · combination
66%
NCT03444766 · Phase 4 · registry result, not featured evidence
64.1%Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.9%Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
73.1%
NCT03117049 · Phase 3 · registry result, not featured evidence
0.3%
NCT02613507 · Phase 3 · registry result, not featured evidence
2.1%Arm A: Nivolumab Plus Platinum-dou
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
2.7%Arm B: Nivolumab Plus Ipilimumab
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
1.5%
NCT02041533 · Phase 3 · registry result, not featured evidence
1.1%480 mg every 4 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
1.6%240 mg every 2 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
—Cohort A: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Cohort B: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
n/a: no completion milestoneNivolumab Monotherapy (Not Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Nivolumab Monotherapy (Pre-Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
88.2%HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
90.6%Non-HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
2.5%Part 1: Treatment A
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
0%Part 2: Treatment C
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
8.7%Arm A - Nivolumab
NCT03158129 · Phase 2 · registry result, not featured evidence
23.8%Arm B - Nivolumab + Ipilimumab
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
0%Arm C - Nivolumab + Chemotherapy
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
9.1%Arm D - Nivolumab + Ipilimumab + C
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
—Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
0%Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
37.9%
NCT02350764 · Phase 2 · registry result, not featured evidence
—600 mg
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone480mg Q4W
NCT03090737 · Phase 2 · registry result, not featured evidence
87.2%Nivolumab+Ipilimumab
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
88.9%Nivolumab+Ipilimumab+Chemotherapy
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone600 mg SC Q6Wg
NCT04181788 · Phase 1/2
show 12 more results
n/a: no completion milestone600 mg SC Q6W
NCT04181788 · Phase 1/2
n/a: no completion milestone600 mg SC Q6W
NCT04181788 · Phase 1/2
n/a: no completion milestone300 mg SC Q4W
NCT04181788 · Phase 1/2
n/a: no completion milestone300 mg SC Q4W
NCT04181788 · Phase 1/2
n/a: no completion milestone300 mg SC Q4W
NCT04181788 · Phase 1/2
86.7%300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
85.3%300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
87.2%300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
85.7%10 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
75%3 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
100%1 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
50%0.5 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—480 mgf
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 43 more results
—3 mg/kg
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.3%Nivolumab
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—480 mg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—3 mg/kg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.7%Nivolumab
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.6%360 mg
NCT02998528 · Phase 3 · combination
0%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · combination
0.3%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3
0%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · combination
0.5%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · combination
0%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · combination
0.3%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · combination
0%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · combination
6%
NCT03444766 · Phase 4 · registry result, not featured evidence
—Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
—Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
—
NCT03117049 · Phase 3 · registry result, not featured evidence
—
NCT02613507 · Phase 3 · registry result, not featured evidence
0.7%Arm A: Nivolumab Plus Platinum-dou
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
0%Arm B: Nivolumab Plus Ipilimumab
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
—
NCT02041533 · Phase 3 · registry result, not featured evidence
—480 mg every 4 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
—240 mg every 2 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
—Cohort A: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Cohort B: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
3.8%Nivolumab Monotherapy (Not Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Nivolumab Monotherapy (Pre-Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
11.8%HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
5%Non-HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
—Part 1: Treatment A
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
—Part 2: Treatment C
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
0%Arm A - Nivolumab
NCT03158129 · Phase 2 · registry result, not featured evidence
4.8%Arm B - Nivolumab + Ipilimumab
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
0%Arm C - Nivolumab + Chemotherapy
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
0%Arm D - Nivolumab + Ipilimumab + C
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
—Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
—Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
13.8%
NCT02350764 · Phase 2 · registry result, not featured evidence
—600 mg
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
5.4%480mg Q4W
NCT03090737 · Phase 2 · registry result, not featured evidence
11.1%Nivolumab+Ipilimumab
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
11.1%Nivolumab+Ipilimumab+Chemotherapy
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
9.4%3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
16.7%600 mg SC Q6Wg
NCT04181788 · Phase 1/2
show 12 more results
0%600 mg SC Q6W
NCT04181788 · Phase 1/2
3.8%600 mg SC Q6W
NCT04181788 · Phase 1/2
0%300 mg SC Q4W
NCT04181788 · Phase 1/2
16.7%300 mg SC Q4W
NCT04181788 · Phase 1/2
2.4%300 mg SC Q4W
NCT04181788 · Phase 1/2
—300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
—300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
—300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
—10 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
—3 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
—1 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
—0.5 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
Serious AEs
33.3%480 mgf
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 43 more results
59.9%3 mg/kg
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—Nivolumab
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
16.7%480 mg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
64.9%3 mg/kg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—Nivolumab
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
30.1%360 mg
NCT02998528 · Phase 3 · combination
27%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · combination
61.1%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3
70.3%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · combination
69.2%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · combination
65.1%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · combination
64%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · combination
61.9%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · combination
30%
NCT03444766 · Phase 4 · registry result, not featured evidence
63.8%Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.9%Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.4%
NCT03117049 · Phase 3 · registry result, not featured evidence
54.3%
NCT02613507 · Phase 3 · registry result, not featured evidence
54.6%Arm A: Nivolumab Plus Platinum-dou
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
64.8%Arm B: Nivolumab Plus Ipilimumab
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
73%
NCT02041533 · Phase 3 · registry result, not featured evidence
34.8%480 mg every 4 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
39.4%240 mg every 2 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
44.9%Cohort A: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
41.6%Cohort B: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Nivolumab Monotherapy (Not Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
60.9%Nivolumab Monotherapy (Pre-Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
70.6%HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
41%Non-HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
59.7%Part 1: Treatment A
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
65.2%Part 2: Treatment C
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
17.4%Arm A - Nivolumab
NCT03158129 · Phase 2 · registry result, not featured evidence
14.3%Arm B - Nivolumab + Ipilimumab
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
31.8%Arm C - Nivolumab + Chemotherapy
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
13.6%Arm D - Nivolumab + Ipilimumab + C
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
37.5%Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
20%Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
75.9%
NCT02350764 · Phase 2 · registry result, not featured evidence
100%600 mg
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
43.4%480mg Q4W
NCT03090737 · Phase 2 · registry result, not featured evidence
59.4%Nivolumab+Ipilimumab
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
72.2%Nivolumab+Ipilimumab+Chemotherapy
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
75.2%3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
0%600 mg SC Q6Wg
NCT04181788 · Phase 1/2
show 12 more results
0%600 mg SC Q6W
NCT04181788 · Phase 1/2
16.3%600 mg SC Q6W
NCT04181788 · Phase 1/2
25%300 mg SC Q4W
NCT04181788 · Phase 1/2
16.7%300 mg SC Q4W
NCT04181788 · Phase 1/2
39%300 mg SC Q4W
NCT04181788 · Phase 1/2
20%300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
26.5%300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
34.2%300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
42.9%10 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
37.5%3 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
37.5%1 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
50%0.5 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
480 mgf
cough 33.3%
arthralgia 20%
rash 20%
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 40 more results
3 mg/kg
fatigue 33.4%
decreased appetite 31.7%
cough 28.9%
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
480 mg
nausea 33.3%
vomiting 33.3%
abdominal pain 16.7%
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
3 mg/kg
dyspnoea 35.9%
cough 34.4%
fatigue 32.1%
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
360 mg
nausea 41.5%
constipation 35.8%
anaemia 35.2%
NCT02998528 · Phase 3 · combination
3 mg/kg + 1 mg/kg
constipation 21.6%
fatigue 21.6%
nausea 21.6%
NCT02998528 · Phase 3 · combination
decreased appetite 24.8%
dyspnoea 23.8%
diarrhoea 22.5%
NCT02477826 · Phase 3
decreased appetite 33.2%
fatigue 27.4%
diarrhoea 26.1%
NCT02477826 · Phase 3 · combination
decreased appetite 33%
dyspnoea 25.4%
diarrhoea 23.8%
NCT02477826 · Phase 3 · combination
anaemia 46.5%
nausea 45.9%
constipation 36.6%
NCT02477826 · Phase 3 · combination
anaemia 46.4%
nausea 33.6%
decreased appetite 28%
NCT02477826 · Phase 3 · combination
anaemia 50%
hyponatraemia 37.3%
aspartate aminotransferase increased 36.5%
NCT02477826 · Phase 3 · combination
cough 24%
pyrexia 21%
vomiting 17%
NCT03444766 · Phase 4 · registry result, not featured evidence
anaemia 44%
nausea 34.8%
constipation 29.1%
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
anaemia 41.5%
nausea 32.7%
cough 26.1%
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
constipation 54.9% (placebo 48.7%)
alopecia 52.4% (placebo 54.5%)
peripheral sensory neuropathy 44.3% (placebo 42.2%)
NCT03117049 · Phase 3 · registry result, not featured evidence
anaemia 34.7%
decreased appetite 31.5%
fatigue 31.2%
NCT02613507 · Phase 3 · registry result, not featured evidence
anaemia 46.8%
nausea 44.7%
constipation 36.9%
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
constipation 29.6%
pruritus 25.4%
diarrhoea 23.9%
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
fatigue 40.4%
decreased appetite 34.1%
nausea 32.2%
NCT02041533 · Phase 3 · registry result, not featured evidence
480 mg every 4 weeks
diarrhoea 16.9%
pruritus 16.9%
fatigue 15.7%
NCT02713867 · Phase 3 · registry result, not featured evidence
240 mg every 2 weeks
pruritus 23.3%
diarrhoea 22.8%
fatigue 22.2%
NCT02713867 · Phase 3 · registry result, not featured evidence
diarrhoea 28.3%
arthralgia 23.6%
upper respiratory tract infection 22%
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
cough 17.6%
weight decreased 16%
arthralgia 14.4%
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
fatigue 36.1%
dyspnoea 23.7%
nausea 23.2%
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
anaemia 41.2%
cough 41.2%
hyponatraemia 35.3%
NCT03195491 · Phase 3 · registry result, not featured evidence
anaemia 40.5%
decreased appetite 24.5%
cough 22.2%
NCT03195491 · Phase 3 · registry result, not featured evidence
anaemia 66.2%
fatigue 42.9%
nausea 42.9%
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
anaemia 69%
nausea 34.8%
thrombocytopenia 29.7%
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
fatigue 34.8%
anemia 30.4%
rash acneiform 26.1%
NCT03158129 · Phase 2 · registry result, not featured evidence
rash acneiform 61.9%
cough 38.1%
fatigue 38.1%
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
nausea 81.8%
fatigue 72.7%
anemia 54.5%
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
anemia 50%
diarrhea 40.9%
nausea 40.9%
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
anemia 62.5%
fatigue 50%
hyponatremia 50%
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
activated partial thromboplastin time prolonged 80%
hypertriglyceridemia 60%
hyponatremia 60%
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
hyperglycemia 100%
hypoalbuminemia 93.1%
anemia 75.9%
NCT02350764 · Phase 2 · registry result, not featured evidence
600 mg
blood alkaline phosphatase increased 100%
blood lactate dehydrogenase increased 100%
bronchitis 100%
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
480mg Q4W
anaemia 28.7%
blood alkaline phosphatase increased 24.8%
rash 20.2%
NCT03090737 · Phase 2 · registry result, not featured evidence
fatigue 55.2%
diarrhoea 38.5%
nausea 38.2%
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
fatigue 55.6%
pruritus 47.2%
nausea 44.4%
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
3 mg/kg
fatigue 53%
decreased appetite 39.3%
dyspnoea 38.5%
NCT01721759 · Phase 2 · registry result, not featured evidence
600 mg SC Q6Wg
pruritus 50%
alanine aminotransferase increased 16.7%
alopecia 16.7%
NCT04181788 · Phase 1/2
show 12 more results
600 mg SC Q6W
anaemia 50%
blood glucose increased 33.3%
blood bilirubin increased 25%
NCT04181788 · Phase 1/2
600 mg SC Q6W
dyspnoea 13.8%
anaemia 12.5%
weight decreased 12.5%
NCT04181788 · Phase 1/2
300 mg SC Q4W
alanine aminotransferase increased 25%
anaemia 25%
aspartate aminotransferase increased 25%
NCT04181788 · Phase 1/2
300 mg SC Q4W
anaemia 33.3%
hypertriglyceridaemia 33.3%
hypoalbuminaemia 33.3%
NCT04181788 · Phase 1/2
300 mg SC Q4W
asthenia 22%
dyspnoea 22%
anaemia 19.5%
NCT04181788 · Phase 1/2
300 mg SC
decreased appetite 46.7%
nausea 40%
dyspnoea 33.3%
NCT02573259 · Phase 1 · registry result, not featured evidence
300 mg SC
anaemia 19.1%
dyspnoea 14.7%
decreased appetite 13.2%
NCT02573259 · Phase 1 · registry result, not featured evidence
300 mg SC
anaemia 31.6%
asthenia 15.8%
back pain 15.8%
NCT02573259 · Phase 1 · registry result, not featured evidence
10 mg/kg IV
generalised oedema 57.1%
constipation 42.9%
aspartate aminotransferase increased 28.6%
NCT02573259 · Phase 1 · registry result, not featured evidence
3 mg/kg IV
generalised oedema 50%
arthralgia 37.5%
blood thyroid stimulating hormone increased 37.5%
NCT02573259 · Phase 1 · registry result, not featured evidence
1 mg/kg IV
constipation 50%
decreased appetite 37.5%
generalised oedema 37.5%
NCT02573259 · Phase 1 · registry result, not featured evidence
0.5 mg/kg IV
back pain 100%
blood creatinine increased 100%
constipation 100%
NCT02573259 · Phase 1 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 1 versus Phase 2.
  2. bPopulation context differs: registered conditions differ.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation comparability has not been reviewed for 38 of these studies.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

Overall Survival NA vs 73.72 Platinum Doublet Chemo months360 mg
time to event · months
NCT02998528 · Phase 3 · combination
show 18 more results
12.19 vs 9.36 Docetaxel months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
12.21 vs 9.49 Docetaxel months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
9.23 vs 6.01 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
9.23 vs 6.01 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
17.12 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
15.7 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3
17.45 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
15.21 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
18.27 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
20.99 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
34.6 vs 39.79 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
39.49 vs 39.79 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
25.4 vs 24.7 placebo months
NCT03117049 · Phase 3 · registry result, not featured evidence
11.99 vs 9.63 Docetaxel months
NCT02613507 · Phase 3 · registry result, not featured evidence
19.35 vs 15.9 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
17.12 vs 15.9 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
14.36 vs 13.21 Investigator Choice of Chemotherapy months
NCT02041533 · Phase 3 · registry result, not featured evidence
13.73 vs 13.8 Investigator Choice of Chemotherapy months
NCT02041533 · Phase 3 · registry result, not featured evidence
ORR 19.5% (n=292) vs 12.8% (n=290) Docetaxel
responder rate · % of participants
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 14 more results
20% (n=135) vs 8.8% (n=137) Docetaxel
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
36.4% (n=396) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
27.5% (n=396) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3
26.2% (n=187) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
37.9% (n=177) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
52.3% (n=377) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
38.1% (n=126) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
67.6% (n=287) vs 64.5% (n=318) Durva
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
72.2% (n=320) vs 64.5% (n=318) Durva
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
61.3% (n=287) vs 57.9% (n=318) Durva
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
63.1% (n=320) vs 57.9% (n=318) Durva
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
61.5% (n=275) vs 50.5% (n=275) placebo
NCT03117049 · Phase 3 · registry result, not featured evidence
26.1% (n=211) vs 33.5% (n=212) Investigator Choice of Chemotherapy
NCT02041533 · Phase 3 · registry result, not featured evidence
50.6% (n=158) vs 43% (n=151) Nivolumab + Chemotherapy @ 64wk
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
Time to Response 2.1 vs 2.73 Docetaxel months
time to event · months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 5 more results
2.23 vs 2.09 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
2.92 vs 2.92 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
2.96 vs 2.92 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
2.96 vs 2.89 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
2.92 vs 2.89 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
Duration of Response 17.15 vs 5.55 Docetaxel months
time to event · months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 9 more results
24.51 vs 8.41 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
25.76 vs 25.17 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
31.84 vs 25.17 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
22.83 vs 27.93 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
33.18 vs 27.93 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
11 vs 7 placebo months
NCT03117049 · Phase 3 · registry result, not featured evidence
6.67 vs 5.55 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
50.04 vs 5.55 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
8.41 vs 7.1 Nivolumab + Chemotherapy months
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
PFS 2.33 vs 4.44 Docetaxel months
time to event · months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 17 more results
3.48 vs 2.83 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
5.06 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · combination
4.17 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3
4.9 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · combination
5.55 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · combination
8.34 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · combination
5.78 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · combination
16.69 vs 15.64 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
16.82 vs 15.67 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
17.38 vs 15.67 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
16.82 vs 16.53 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
17.71 vs 16.53 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
12.1 vs 8.1 placebo months
NCT03117049 · Phase 3 · registry result, not featured evidence
5.59 vs 5.45 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
1.54 vs 5.45 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
4.21 vs 5.88 Investigator Choice of Chemotherapy months
NCT02041533 · Phase 3 · registry result, not featured evidence
4.21 vs 5.82 Investigator Choice of Chemotherapy months
NCT02041533 · Phase 3 · registry result, not featured evidence
Disease-related Symptom Improvement 17.8% (n=292) vs 19.7% (n=290) Docetaxel @ 12wk
responder rate · % of participants
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 2 more results
18.5% (n=135) vs 21.2% (n=137) Docetaxel @ 12wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
35.4% (n=271) vs 33.7% (n=270) Investigator Choice of Chemotherapy @ 12wk
NCT02041533 · Phase 3 · registry result, not featured evidence
Overall Survival 63.7% (n=135) vs 50.7% (n=137) Docetaxel @ 26wk
absolute value · percentage points
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 11 more results
42.2% (n=135) vs 24.3% (n=137) Docetaxel @ 52wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
28.1% (n=135) vs 12.5% (n=137) Docetaxel @ 78wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
63.7% (n=135) vs 50.4% (n=137) Docetaxel @ 26wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
42.2% (n=135) vs 24.1% (n=137) Docetaxel @ 52wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
28.1% (n=135) vs 12.4% (n=137) Docetaxel @ 78wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
23% (n=135) vs 8% (n=137) Docetaxel @ 104wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
15.6% (n=135) vs 5.8% (n=137) Docetaxel @ 156wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
13.1% (n=135) vs 4.4% (n=137) Docetaxel @ 208wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
12.3% (n=135) vs 3.6% (n=137) Docetaxel @ 260wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
11.4% (n=135) vs 2.7% (n=137) Docetaxel @ 312wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
9.6% (n=135) vs 0% (n=137) Docetaxel @ 364wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
PFS 38.4% (n=135) vs 22.6% (n=137) Docetaxel @ 26wk
responder rate · % of participants
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 8 more results
21% (n=135) vs 7.2% (n=137) Docetaxel @ 52wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
15.87% (n=135) vs 1.8% (n=137) Docetaxel @ 78wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
14.8% (n=135) vs NA Docetaxel @ 104wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
11% (n=135) vs NA Docetaxel @ 156wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
8.9% (n=135) vs NA Docetaxel @ 208wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
8.9% (n=135) vs NA Docetaxel @ 260wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
7.6% (n=135) vs NA Docetaxel @ 312wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
6.1% (n=135) vs NA Docetaxel @ 364wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Event-Free Survival 31.57 vs 20.8 Platinum Doublet Chemo months360 mg
time to event · months
NCT02998528 · Phase 3 · combination
show 1 more result
59.6 vs 21.06 Platinum Doublet Chemo months360 mg
NCT02998528 · Phase 3 · combination
Pathologic Complete 24% (n=179) vs 2.2% (n=179) Platinum Doublet Chemo360 mg
responder rate · % of participants
NCT02998528 · Phase 3 · combination · converted to % from 43 Participants as posted
Major Pathologic 36.9% (n=179) vs 8.9% (n=179) Platinum Doublet Chemo360 mg
responder rate · % of participants
NCT02998528 · Phase 3 · combination · converted to % from 66 Participants as posted
Time to Death or Distant Metastasis 64.66 vs 36.76 Platinum Doublet Chemo months360 mg
time to event · months
NCT02998528 · Phase 3 · combination
show 2 more results
30.65 vs 30.36 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
36.14 vs 30.36 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination

+ 39 further endpoints in the CSV export.

Sasanlimab

ORR 6.7% (n=15)300 mg SC
event count · % of participants
No placebo or comparator arm
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
show 9 more results
6.7% (n=15)*300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
28.6% (n=7)*10 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 2 Participants as posted
28.6% (n=7)*10 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 2 Participants as posted
12.5% (n=8)*3 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
12.5% (n=8)*3 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
28.6% (n=7)*1 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 2 Participants as posted
28.6% (n=7)*1 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 2 Participants as posted
50% (n=2)*0.5 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
50% (n=2)*0.5 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
PFS 3 months300 mg SC
time to event · months
No placebo or comparator arm
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
show 2 more results
3.7 months300 mg SC
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
2.9 months300 mg SC
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
Duration of Response NA months300 mg SC
time to event · months
No placebo or comparator arm
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
show 2 more results
21.8 months300 mg SC
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
13.9 months300 mg SC
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
Time to Response 2.71 months300 mg SC
time to event · months
No placebo or comparator arm
NCT02573259 · Phase 1 · registry result, not featured evidence
show 1 more result
2.33 months300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
Time to Progression 3.7 months300 mg SC
time to event · months
No placebo or comparator arm
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
show 1 more result
3.7 months300 mg SC
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
Overall Survival 0.773 Probability @ 26wk300 mg SC
absolute value · Probability
No placebo or comparator arm
NCT02573259 · Phase 1 · registry result, not featured evidence
show 5 more results
0.711 Probability @ 26wk300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
0.547 Probability @ 52wk300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
0.471 Probability @ 52wk300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
0.403 Probability @ 104wk300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
0.286 Probability @ 104wk300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Nivolumab's landscape · Sasanlimab's landscape